Lead Product(s) : Quemliclustat,Etrumadenant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Taiho Exercises License Option for Quemliclustat in Japan and Asia
Details : Under the license agreement, Taiho will further support the development & commercialization of AB680 (quemliclustat) & will operationalize the PRISM-1 study in Japan as part of its mission.
Product Name : AB680
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 07, 2024
Lead Product(s) : Quemliclustat,Etrumadenant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Domvanalimab,Etrumadenant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Arcus Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.
Product Name : AB154
Product Type : Antibody
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Domvanalimab,Etrumadenant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Arcus Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Domvanalimab,Etrumadenant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Arcus Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.
Product Name : AB154
Product Type : Antibody
Upfront Cash : Inapplicable
November 28, 2022
Lead Product(s) : Domvanalimab,Etrumadenant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Arcus Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Domvanalimab,Etrumadenant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARC-7 and the ongoing ARC-10 Phase 3 registrational study will continue to enroll as planned, and preparations for additional Phase 3 studies are underway for domvanalimab-based combinations across various cancer types.
Product Name : AB154
Product Type : Antibody
Upfront Cash : Inapplicable
June 24, 2021
Lead Product(s) : Domvanalimab,Etrumadenant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eganelisib,Etrumadenant
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Arcus Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Infinity to Present at New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021
Details : The Phase 1b clinical trial is a global multi-center, open-label trial of CERC-007 that will enroll around 12 subjects with active adult onset Still’s disease with a primal goal of the study will be to determine the safety and tolerability of CERC-007 ...
Product Name : IPI-549
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2021
Lead Product(s) : Eganelisib,Etrumadenant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Arcus Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable